Status:
COMPLETED
Peripheral Dopamine in Postural Tachycardia Syndrome
Lead Sponsor:
Vanderbilt University
Conditions:
Postural Tachycardia Syndrome
Orthostatic Intolerance
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
PHASE3
Brief Summary
The purpose of the proposed research is to determine how changes in kidney dopamine (DA) activity influence urinary sodium excretion. We will decrease DA activity in the kidney by inhibiting DA synthe...
Detailed Description
We will determine whether inhibition of renal dopamine formation by carbidopa administration leads to a decrease in urinary excretion of dopamine and sodium and whether the response differs in POTS an...
Eligibility Criteria
Inclusion
- Patients diagnosed with POTS by the Vanderbilt Autonomic Dysfunction Center based on the following stringent criteria: 1) history of daily orthostatic symptoms for at least 6 months; 2) increase in heart rate (HR) of at least 30 bpm with standing or a standing HR of at least 120 bpm; 3) absence of orthostatic hypotension (defined as a fall in blood pressure (BP)\>20/10 mm Hg); and 4) absence of conditions, such as dehydration, substantial weight loss, or systemic illnesses, that could provoke orthostatic intolerance
- Upright plasma NE at least 600 pg/mL in patients
- Non-smoking
- Free of medications with the potential to influence BP
- Able and willing to provide informed consent -
Exclusion
- Overt cause for postural tachycardia (such as acute dehydration)
- Significant cardiovascular, pulmonary, hepatic, or hematological disease by history or screening results
- Positive urine b-hcg pregnancy test
- Evidence of cardiac structural disease (by clinical examination or prior echocardiogram)
- Hypertension defined as a BP\>145/95 (off medications) or need for antihypertensive medications
- Evidence of significant conduction system delay (QRS duration \>120 ms) on electrocardiogram
- Inability to give, or withdraw, informed consent
Key Trial Info
Start Date :
May 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2021
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT00685919
Start Date
May 1 2008
End Date
December 1 2021
Last Update
January 24 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232